The Latest Breaking News from AstraZeneca

With a robust portfolio, this top pharma stock is a good mix of growth and income.

Twelve families have dropped their cases, according to reports

All ‘Adverse Events Following Immunisation’ (AEFI) after COVID-19 vaccinations continue to be monitored, a senior official said.

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." Read further on Dynamite News:

Controversy over Covishield safety reaches Supreme Court, petition seeks expert panel to study risk factors and vaccine consequences.

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Soriot came under fire this month for his £18.7 million pay packet

City Voices: Taken together, London’s top flight mightn’t look so appealing. But that doesn’t mean that all UK stocks should be written off.

The biotech industry’s growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more.

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere

AstraZeneca shareholders approve 2024 pay policy, showing confidence in CEO Soriot's leadership and company's future growth.